key: cord-0949728-x2tn2kqp authors: Martinez, Miguel Angel title: What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2? date: 2022-02-16 journal: Front Microbiol DOI: 10.3389/fmicb.2022.843587 sha: dee4319058912708c77a6ee21414772d10903652 doc_id: 949728 cord_uid: x2tn2kqp nan in evidence-based medicine (Cross et al., 2021) . Therefore, clinical trials and methodologies for identifying effective drugs should be designed based on methodologies with the highest likelihood of success. Antiviral drugs target key processes in the virus life cycle. These processes include virus cell entry, genome replication, translation, protein processing, and virus particle generation. More than two-thirds of all antivirals approved for human use target viral enzymes, such as viral RNA/DNA polymerases and viral proteases (De Clercq and Li, 2016; Tompa et al., 2021) . Importantly, in the last 30 years, no antiviral drug has been approved in the absence of a specific viral target. Thus, perhaps the main drawback of the repurposed antiviral drugs that have been tested unsuccessfully against SARS-CoV-2 has been the absence of an evident mechanism of action ( Table 1) . Hits from antiviral screening based on biochemical or cellculture assays must be treated with skepticism. Chloroquine and hydroxychloroquine represent a clear example of misinterpreted cell culture results. The efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 in tissue cultures was determined with African green monkey kidney-derived Vero cells. However, when Vero cells were engineered to express TMPRSS2, a cellular protease that activates SARS-CoV-2 for entry into lung cells, the genetic manipulation rendered SARS-CoV-2-infected Vero cells insensitive to chloroquine (Hoffmann et al., 2020) . Accordingly, chloroquine could not block SARS-CoV-2 infections in TMPRSS2-expressing human lung Calu-3 cells; thus, chloroquine targets a viral activation pathway that is not present in human lung cells. Therefore, the drug is unlikely to protect against the spread of SARS-CoV-2. Another example of a misinterpretation of cell culture results was recently reported (Tummino et al., 2021) in a study that demonstrated that phospholipidosis was a shared mechanism underlying the antiviral activity of many repurposed drugs for SARS-CoV-2 (Tummino et al., 2021) . Conversely, drugs that were active against the same targets, but did not induce phospholipidosis, were not effective against viruses. Those results strongly suggested that a failure to induce phospholipidosis could explain why most drugs that were selected for repurposing to date lacked clinical efficacy against SARS-CoV-2. In future pandemics, the target specificity of candidate antivirals should be examined before initiating treatment to exclude non-specific mechanisms during drug development. Target specificity should be accompanied by safety profiles and a determination of the pharmacokinetics/pharmacodynamics of selected drugs. Viruses manipulate many cellular processes during their life-cycles; thus, when a tested drug modifies a cellular pathway, it frequently leads to a false-positive hit. Even when a drug mechanism of action is known, the preclinical data must be interpreted with caution. At the beginning of the SARS-CoV-2 pandemic, remdesivir, developed by Gilead, was the most promising antiviral drug for combating SARS-CoV-2. Initial interest in the drug was based on its potency in cell culture models of SARS-CoV-2, including primary human airway epithelial cells (Pruijssers et al., 2020) . Moreover, remdesivir displayed specificity against the RNAdependent RNA polymerase (RdRp) of other coronaviruses (Agostini et al., 2018) , such as SARS-CoV and MERS-CoV. Moreover, it showed prophylactic and therapeutic efficacy in a rhesus macaque model of a MERS-CoV infection (de Wit et al., 2020) . However, the clinical efficacy of remdesivir for COVID-19 remains controversial. Several trials have found no significant differences between remdesivir-treated and control groups in the time-to-clinical-improvement or mortality (Yan and Muller, 2021) . Previous work with remdesivir also showed impressive preclinical and animal-model results against Ebola virus (Warren et al., 2016) ; however, those results were not confirmed in clinical studies (Mulangu et al., 2019) . In severe cases, SARS-CoV-2 induces an overexpression of inflammatory cytokines. Accordingly, immunomodulatory therapies, such as Anakinra (anti-interleukin 1b) and Tocilizumab (anti-interleukin 6), were repurposed for COVID-19. However, monotherapies with these compounds were unsuccessful. Remarkably, broad-spectrum immunemodulators, such as dexamethasone or baricitinib (anti-Janus kinase) have shown better efficacy in severe COVID-19 cases (Tomazini et al., 2020; Abani et al., 2021; Kalil et al., 2021) . The pathogenesis of COVID-19 is different from those of other respiratory diseases. Consequently, repurposing immunomodulatory therapies might be more difficult than initially thought. Additionally, immunomodulatory therapies that might be useful for severe COVID-19 might be harmful in mild or moderate COVID-19, where the immune system can work effectively to control viral replication and disease (Cross et al., 2021) . Historically, repurposing drugs has only been successful in a few cases (Edwards, 2020) . Examples are aspirin, for treating coronary artery disease; erythromycin, for treating impaired gastric motility; sildenafil for treating erectile dysfunction; thalidomide for treating multiple myeloma; and imatinib for treating gastrointestinal stromal tumors (Corsello et al., 2017) . Most of those achievements were serendipitous. Nevertheless, those chance discoveries have promoted systematic searches for other drugs that might be repurposed. These explorations have mainly relied on high-throughput screening technologies and computational modeling with large datasets (Edwards, 2020) . Currently, several libraries of approved drugs are available for rapid screening to identify candidates for repurposing against the targeted disease. Unfortunately, systematic, hypothesis-free, large-scale screening of these drug libraries has yet to yield effective treatments for most targeted diseases. Effective vaccines against SARS-CoV-2 have been developed with extraordinary speediness. Vaccines have prevented COVID-19 development, but they have not generated sterilizing immunity in a significant percentage of individuals; thus, viral transmission remains possible after a vaccination (Krammer, 2020; Cromer et al., 2021) . The continuous emergence of SARS-CoV-2 variants, such as the Delta or Omicron variant, has challenged the efficacy of current vaccines. The Omicron outbreak in southern Africa might be due to its capacity to infect people that have been vaccinated or have recovered from COVID-19 caused by Delta and other variants. At this stage, there is a need for an antiviral that effectively combats SARS-CoV-2 to prevent more severe disease, hospitalizations, and deaths. A combination of vaccines and antiviral drugs should be a powerful tool for controlling the morbidity, mortality, and spread of SARS-CoV-2. Antivirals should target SARS-CoV-2 infections early to prevent rapid viral replication. In addition to the approved antiviral, remdesivir, which is delivered intravenously, two additional oral drugs, molnupiravir and nirmatrelvir (paxlovid), have completed human phase 3 clinical trials and have been approved (Table 2) . Molnupiravir, a cytidine ribonucleoside analog first developed to inhibit influenza virus replication, was shown to inhibit the SARS-CoV-2 RdRp (Painter et al., 2021) . Molnupiravir can pair ambiguously, as cytidine or uridine, with viral RNA. This pairing introduces an elevated mutation load that generates non-infectious virus particles. Molnupiravir, promoted by Merck for SARS-CoV-2 clinics, has the potential to be a broad-based inhibitor; it acts against a number of RNA viruses, including seasonal influenza virus, MERS-CoV, and encephalitic alphaviruses, such as Venezuelan, Eastern, and Western equine encephalitis viruses. Phase 3 clinical trial data from Merck have shown that a 5-day course of molnupiravir reduced hospitalization or mortality by ∼50%, compared to placebo, in patients with mild or moderate COVID-19. Nevertheless, the efficacy of molnupiravir was reduced from 50 to 30% in the published peer-reviewed data of the former phase 3 trial (Jayk Bernal et al., 2021) . Nirmatrelvir inhibits the main SARS-CoV-2 protease (Owen et al., 2021) . Protease inhibitors have been shown to be powerful antivirals, as demonstrated with human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). In a phase 3 clinical trial, nirmatrelvir was combined with ritonavir, an HIV-1 protease inhibitor that prevents enzymes in the liver from breaking down the antiviral. This combination showed 89% efficacy in preventing COVID-19 hospitalization and death. Still, the data for nirmatrelvir, generated by Pfizer, have not yet been peer-reviewed. These two promising antivirals will probably be effective against SARS-CoV-2 variants of concern, because these variants are characterized by mutations in the viral spike protein and other regions that are targeted by the immune system and/or by vaccines. Nevertheless, it should not be overlooked that monotherapy with any of these antivirals may induce viral drug resistance. This has been a familiar problem with other virus infections, like HIV-1 and HCV, which require treatments with a combination of antiviral drugs. The emergence of new human viruses, such as HIV-1, HCV, Ebola virus, and Zika virus, has taught us that every new emerging virus has a distinct life style and a pathogenic course that was unknown in preceding viral infections. Moreover, SARS-CoV-2 is likely to become a permanent, endemic virus, like the previous, recently emerged human viruses. Repurposing drugs has been an appealing strategy for the rapid translation of drugs to the clinic. However, despite the enthusiasm for this strategy, it has not produced any effective treatments for COVID-19, or any other viral disease, including those caused by recent emergent viruses, such as Zika virus and Ebola virus. Drug development requires time, funding, and collaboration among clinical investigators, virologists, immunologists, and pharmacologists. It is important to know and understand the drug's target, toxicity, and pharmacodynamics, in addition to the key viral kinetic time-points and specific (or broad) immune phenomena. This approach may take more time, but it could be useful for fighting SARS-CoV-2 and for developing drugs to combat newly emerging viruses and future pandemics. The author confirms being the sole contributor of this work and has approved it for publication. This work was supported by the Spanish Ministry of Science and Innovation (PID2019-103955RB-100). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials Coronapod: ivermectin, what the science says A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 The Drug Repurposing Hub: a next-generation drug library and information resource Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection Emergency drug use in a pandemic: harsh lessons from COVID-19 Nuisance compounds in cellular assays Approved antiviral drugs over the past 50 years Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19 2020). screen? No shortcuts to SARS-CoV-2 antivirals COVID-19 does not lead to a "typical" acute respiratory distress syndrome Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients Baricitinib plus remdesivir for hospitalized adults with COVID-19 SARS-CoV-2 vaccines in development Compounds with therapeutic potential against novel respiratory 2019 coronavirus Lack of effectiveness of repurposed drugs for COVID-19 treatment A randomized, controlled trial of ebola virus disease therapeutics An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2 Ivermectin for preventing and treating COVID-19 Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice The trinity of COVID-19: immunity, inflammation and intervention Effect of dexamethasone on days alive and ventilatorfree in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Why remdesivir failed: Preclinical assumptions overestimate the clinical efficacy of remdesivir for COVID-19 and Ebola Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2022 Martinez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.